The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of body mass index on treatment and outcomes in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial.
 
Georg Pfeiler
Honoraria - Accord Healthcare; Amgen; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Lilly; Novartis; Pfizer; Roche/Genentech; UCB
Consulting or Advisory Role - Amgen; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Lilly; Novartis; Pfizer; Roche/Genentech; UCB
Speakers' Bureau - Accord Healthcare; Amgen; AstraZeneca/Daiichi Sankyo; AstraZeneca/Merck; Lilly; Novartis; Pfizer; Roche/Genentech; UCB
Research Funding - Accord Healthcare; Pfizer; Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca/Daiichi Sankyo; Lilly; Lilly; Novartis; Roche/Genentech
 
Dominik Hlauschek
Research Funding - Pfizer (Inst)
 
Erica L. Mayer
Consulting or Advisory Role - AstraZeneca; Gilead Sciences; Lilly; Novartis
Research Funding - Pfizer (Inst)
 
Christine Deutschmann
Consulting or Advisory Role - Roche
Travel, Accommodations, Expenses - Motiva
 
Stephanie Kacerovsky-Strobl
No Relationships to Disclose
 
Miguel Martin
Honoraria - Lilly; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Seagen
Consulting or Advisory Role - AstraZeneca; Daiichi-Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech
Speakers' Bureau - Lilly/ImClone; Lilly/ImClone; Pierre Fabre; Roche/Genentech
Research Funding - Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Other Relationship - Novartis; Roche
 
Jane Lowe Meisel
Honoraria - Medscape; Total Health Conferencing
Consulting or Advisory Role - AstraZeneca; Curio Science; Genentech; GlaxoSmithKline; Novartis; Seagen
Research Funding - Pfizer; Seagen
Travel, Accommodations, Expenses - Pfizer; Puma Biotechnology; Total Health Conferencing
 
Nicholas Zdenkowski
Honoraria - AstraZeneca; Eisai; Lilly; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly
Research Funding - Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Novartis; Roche
 
Sibylle Loibl
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); EirGenix (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Lilly (Inst); Medscape (Inst); Merck KGaA (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Puma Biotechnology (Inst); Roche (Inst); Seagen (Inst)
Speakers' Bureau - AstraZeneca (Inst); Daiichi Sankyo Europe GmbH (Inst); Medscape (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Samsung (Inst)
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Gilead Sciences (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Digital Ki67 Evaluator, VM Scope GmbH (Inst); Patent Issued EP15702464.7 (Inst); Patent Pending EP14153692.0 (Inst); Patent Pending EP19808852.8 (Inst); Patent Pending EP21152186.9 (Inst)
 
Marija Balic
Consulting or Advisory Role - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pfizer; Pierre Fabre; Roche; Samsung; Seagen
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Pierre Fabre; Roche; Seagen
Research Funding - Lilly (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - MSD
 
Haeseong Park
Research Funding - Ambrx (Inst); Amgen (Inst); Aprea Therapeutics (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BJ Bioscience (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Five Prime Therapeutics (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); ImmuneOncia (Inst); Immunomedics (Inst); Incyte (Inst); Jounce Therapeutics (Inst); Lilly (Inst); MabSpace Biosciences (Inst); Macrogenics (Inst); MedImmune (Inst); Medivation (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Oncologie (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Synermore Biologics (Inst); Taiho Pharmaceutical (Inst); Top Alliance BioScience (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); Vertex (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bayer; Daiichi Sankyo; Vedanta Biosciences
 
Aleix Prat
Employment - Novartis (I)
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - Amgen; Daiichi Sankyo; Guardant Health; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; NanoString Technologies (Inst); Novartis; Oncolytics; Pfizer; Puma Biotechnology; Roche
Research Funding - Incyte (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; WO/2018/096191. Chemoendocrine score (CES) Based on PAM50 for breast cancer with positive hormone receptors with an intermediate risk of recurrence
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Claudine Isaacs
Consulting or Advisory Role - AstraZeneca/MedImmune; bioTheranostics; Eisai; Genentech/Roche; Ion Solutions; Novartis; Pfizer; Puma Biotechnology; Sanofi/Aventis; Seagen
Research Funding - Merck (Inst); Seagen (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier - Editor of Book; McGraw Hill Publishing; UpToDate - Wolters Kluwer - Author of chapters
Other Relationship - Side-Out Foundation
 
Jana Machacek-Link
No Relationships to Disclose
 
Celine Schurmans
Research Funding - AstraZeneca (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); SERVIER (Inst)
Patents, Royalties, Other Intellectual Property - My organization receives royalties from Agendia. (Inst)
 
Kathy Puyana Theall
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
Honoraria - Pfizer
Travel, Accommodations, Expenses - Pfizer
 
Christian Fesl
Research Funding - Amgen (Inst); Pfizer (Inst)
 
Amylou C. Dueck
Patents, Royalties, Other Intellectual Property - Royalties from licensing fees for a patient symptom questionnaire (MPN-SAF)
 
Angela DeMichele
Research Funding - Calithera Biosciences (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst)
 
Michael Gnant
Employment - Sandoz (I)
Honoraria - Amgen; AstraZeneca; Lilly; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Daiichi-Sankyo; LifeBrain; Lilly; Tolmar; Veracyte